3-氯-5-苯基-1,2,4-噻二唑 | 101495-56-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 中文名称: 3-氯-5-苯基-1,2,4-噻二唑
• 英文名称: 3-Chlor-5-phenyl-1,2,4-thiodiazol
• 英文别名: 3-Chloro-5-phenyl-1,2,4-thiadiazole
• CAS: 101495-56-1
• 化学式: C₈H₅ClN₂S
• 分子量: 196.66
• InChiKey: ZGROIHXQCKYCPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-氯-5-苯基-1,2,4-噻二唑 、 N,N-二甲基乙酰胺 在 sodium hexamethyldisilazane 作用下， 以 甲苯 为溶剂， 反应 14.0h， 以69%的产率得到N,N-Dimethyl-2-(5-phenyl-[1,2,4]thiadiazol-3-yl)-acetamide
  参考文献：
  名称：

  α-Heteroarylation of Esters, Lactones, Amides, and Lactams by Nucleophilic Aromatic Substitution

  摘要：

  A mild and efficient alpha-heteroarylation of simple esters and amides was developed via nucleophilic aromatic substitution. The choice of NaHMDS in toluene gave the best results. A tandem a-heteroarylation and hydroxylation protocol using air as the oxidant afforded tertiary alcohols in good yields.

  DOI：

  10.1021/ol060246u
• 作为产物：
  描述：

  3-氨基-5-苯基-1,2,4-噻二唑 生成 3-氯-5-苯基-1,2,4-噻二唑
  参考文献：
  名称：

  650.噻二唑。第九部分 3-氨基-1,2,4-噻二唑衍生的重氮盐的反应

  摘要：

  DOI：

  10.1039/jr9600003234

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS HÉTÉROCYCLIQUES COMME INHIBITEURS DE C-KIT ET PDGFR KINASE
  申请人：IRM LLC

  公开号：WO2009105712A1

  公开（公告）日：2009-08-27

  The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.

  这项发明提供了一类新型的化合物，其化学式为：(I) 制备包含这类化合物的药物组合物，用于治疗或预防与异常或失调的激酶活性相关的疾病或紊乱，特别是涉及c-kit、PDGFRα和PDGFRβ激酶异常活化的疾病或紊乱。
• Novel quinuclidine derivatives and their use
  申请人：Peters Dan

  公开号：US20050245567A1

  公开（公告）日：2005-11-03

  This invention relates to novel quinuclidine derivatives and their use as pharmaceuticals. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及新型的莨菪碱衍生物及其作为药物的使用。由于它们的药理特性，本发明中的化合物可能对治疗与中枢神经系统（CNS）和外周神经系统（PNS）的胆碱能系统有关的疾病或疾患、与平滑肌收缩有关的疾病或疾患、内分泌疾病或疾患、神经退行性疾病或疾患、与炎症、疼痛有关的疾病或疾患以及因化学物质滥用终止而引起的戒断症状可能有用。
• NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE
  申请人：PETERS Dan

  公开号：US20090005390A1

  公开（公告）日：2009-01-01

  This invention relates to novel quinuclidine derivatives and their use as pharmaceuticals. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及新型的蒽环啶衍生物及其作为药物的用途。由于它们的药理特性，本发明中的化合物可能对多种与中枢神经系统（CNS）、外周神经系统（PNS）、平滑肌收缩有关的疾病或紊乱，内分泌疾病或紊乱，神经退行性疾病或紊乱，炎症、疼痛以及由于滥用化学物质而导致的戒断症状等疾病或紊乱有用。
• HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
  申请人：Chianelli Donatella

  公开号：US20110183997A1

  公开（公告）日：2011-07-28

  The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.

  本发明提供了一类新型的化合物，其化学式为I：(I)，以及包含这些化合物的药物组合物，用于治疗或预防与异常或失调的激酶活性相关的疾病或障碍，尤其是涉及异常激活c-kit、PDGFRα和PDGFRβ激酶的疾病或障碍。
• Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors
  申请人：IRM LLC

  公开号：US08278452B2

  公开（公告）日：2012-10-02

  The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.

  本发明提供了一种新型的I式化合物类：(I)，以及包含这些化合物的制药组合物，用于治疗或预防与异常或调节失常的激酶活性相关的疾病或障碍，尤其是涉及c-kit、PDGFRα和PDGFRβ激酶异常活化的疾病或障碍。